Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Orgenesis (OTCQX:ORGS) has secured an equity line of credit of up to $5 million from Williamsburg Venture Holdings, a Nevada-based family office. The agreement includes an initial $750,000 payment upon registration statement effectiveness, with the remaining $4.25 million available over 24 months.
The purchase price for shares will be 90% of the market price, calculated as the average of the two lowest Volume-Weighted Average Prices (VWAP) over five consecutive trading days. The company can also opt for an accelerated purchase notice by 11:00 AM on any day, with the price set at that day's lowest traded price.
The funding aims to accelerate the rollout of Orgenesis's decentralized Cell and Gene Therapy (CGT) platform and support the development and commercialization of their therapeutic pipeline through their POCare platform.
Orgenesis (OTCQX:ORGS) ha garantito una linea di credito azionario fino a 5 milioni di dollari da Williamsburg Venture Holdings, un family office con sede in Nevada. L'accordo prevede un pagamento iniziale di 750.000 dollari all'entrata in vigore della dichiarazione di registrazione, con i restanti 4,25 milioni di dollari disponibili in 24 mesi.
Il prezzo di acquisto delle azioni sarà pari al 90% del prezzo di mercato, calcolato come la media dei due prezzi medi ponderati per il volume (VWAP) più bassi su cinque giorni di negoziazione consecutivi. L'azienda può anche optare per un avviso di acquisto accelerato entro le 11:00 di qualsiasi giorno, con il prezzo fissato al prezzo più basso trattato quel giorno.
Il finanziamento mira ad accelerare il lancio della piattaforma decentralizzata di Terapia Cellulare e Genica (CGT) di Orgenesis e a supportare lo sviluppo e la commercializzazione del loro pipeline terapeutico attraverso la loro piattaforma POCare.
Orgenesis (OTCQX:ORGS) ha asegurado una línea de crédito de capital de hasta 5 millones de dólares de Williamsburg Venture Holdings, una oficina familiar con sede en Nevada. El acuerdo incluye un pago inicial de 750,000 dólares al momento de la efectividad de la declaración de registro, con los restantes 4.25 millones de dólares disponibles durante 24 meses.
El precio de compra de las acciones será el 90% del precio de mercado, calculado como el promedio de los dos precios promedio ponderados por volumen (VWAP) más bajos durante cinco días comerciales consecutivos. La empresa también puede optar por un aviso de compra acelerado antes de las 11:00 AM de cualquier día, con el precio establecido en el precio negociado más bajo de ese día.
El financiamiento tiene como objetivo acelerar el despliegue de la plataforma descentralizada de Terapia Celular y Genética (CGT) de Orgenesis y apoyar el desarrollo y la comercialización de su pipeline terapéutico a través de su plataforma POCare.
Orgenesis (OTCQX:ORGS)는 네바다에 본사를 둔 가족 사무실인 Williamsburg Venture Holdings로부터 최대 500만 달러의 주식 신용 한도를 확보했습니다. 이 계약에는 등록 선언의 효력 발생 시점에 75만 달러의 초기 지급이 포함되며, 나머지 425만 달러는 24개월 동안 사용할 수 있습니다.
주식 구매 가격은 시장 가격의 90%로, 연속 5거래일 동안 두 개의 최저 거래량 가중 평균 가격(VWAP)의 평균으로 계산됩니다. 회사는 또한 하루에 오전 11시까지 가속 구매 통지를 선택할 수 있으며, 이 경우 가격은 해당 일의 최저 거래 가격으로 설정됩니다.
이번 자금 조달은 Orgenesis의 분산형 세포 및 유전자 치료(CGТ) 플랫폼의 롤아웃을 가속화하고 POCare 플랫폼을 통해 치료 파이프라인의 개발 및 상업화를 지원하는 것을 목표로 하고 있습니다.
Orgenesis (OTCQX:ORGS) a obtenu une ligne de crédit par actions allant jusqu'à 5 millions de dollars de Williamsburg Venture Holdings, un family office basé au Nevada. L'accord inclut un paiement initial de 750 000 dollars lors de l'entrée en vigueur de la déclaration d'enregistrement, les 4,25 millions de dollars restants étant disponibles sur 24 mois.
Le prix d'achat des actions sera de 90 % du prix du marché, calculé comme la moyenne des deux prix moyens pondérés par le volume (VWAP) les plus bas sur cinq jours de négociation consécutifs. L'entreprise peut également opter pour un avis d'achat accéléré avant 11h00 tout jour, le prix étant fixé au prix le plus bas négocié ce jour-là.
Le financement vise à accélérer le déploiement de la plateforme décentralisée de thérapie cellulaire et génique (CGT) d'Orgenesis et à soutenir le développement et la commercialisation de leur pipeline thérapeutique via leur plateforme POCare.
Orgenesis (OTCQX:ORGS) hat eine Kapital-Kreditlinie von bis zu 5 Millionen Dollar von Williamsburg Venture Holdings, einem Familienbüro mit Sitz in Nevada, gesichert. Die Vereinbarung umfasst eine anfängliche Zahlung von 750.000 Dollar bei Wirksamkeit der Registrierungsbehauptung, wobei die verbleibenden 4,25 Millionen Dollar über 24 Monate verfügbar sind.
Der Kaufpreis für die Aktien beträgt 90 % des Marktpreises, der als Durchschnitt der beiden niedrigsten volumengewichteten Durchschnittspreise (VWAP) über fünf aufeinanderfolgende Handelstage berechnet wird. Das Unternehmen kann auch bis 11:00 Uhr an jedem Tag eine beschleunigte Kaufmitteilung wählen, wobei der Preis zu diesem Zeitpunkt auf dem niedrigsten gehandelt Preis des Tages festgelegt ist.
Die Finanzierung dient dazu, den Rollout der dezentralen Zell- und Gentherapie (CGT)-Plattform von Orgenesis zu beschleunigen und die Entwicklung und Kommerzialisierung ihres therapeutischen Portfolios über die POCare-Plattform zu unterstützen.
- Secured up to $5 million in equity financing
- Flexible 24-month drawdown structure
- 10% discount to market price on share issuance
- Potential shareholder dilution through new share issuance
- Share price dependent on future market conditions
- Financing through equity rather than revenue generation
Funding Aimed at Accelerating Rollout of Decentralized CGT Platform
GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded an agreement for an equity line of credit of up to
Under the terms of the agreement, Orgenesis will receive
Vered Caplan, CEO of Orgenesis, commented, "We are deeply appreciative of Williamsburg Venture Holdings' confidence in Orgenesis and their commitment to support the continued growth of our business. This strategic investment aligns with our mission to bring innovative CGT solutions to market by leveraging our proprietary POCare platform. These additional resources will aid in accelerating the development and commercialization of our pipeline, furthering our vision of democratizing access to life-saving therapies."
The per share purchase price for the put shares shall be
Additional details regarding the equity investment are available in the Company's Form 8-K, which has been filed with the U.S. Securities and Exchange Commission.
About Orgenesis
Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost-effectively and with better outcomes through great science and decentralized production. Additional information about the Company is available at: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates, and projections and reflect our beliefs and assumptions based on information available to us as of the date of this release. Forward-looking statements include, but are not limited to, statements regarding the potential impact of the equity investment, the development and commercialization of our POCare platform, our pipeline, and our decentralized CGT platform. We caution readers that forward-looking statements are predictions based on our current expectations about future events and are not guarantees of future performance. Actual results, performance, or achievements may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, our reliance on our point-of-care cell therapy platform, our ability to achieve and maintain profitability, outcomes of clinical trials, timing of clinical trial completions, the potential uses of our product candidates, our ability to manage potential disruptions, sufficiency of working capital, and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statements for any reason.
IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
SOURCE: Orgenesis Inc
View the original press release on ACCESS Newswire
FAQ
What is the total value of Orgenesis (ORGS) equity investment from Williamsburg Venture Holdings?
How will the $5 million investment in ORGS be structured?
What is the share purchase price formula for ORGS under this agreement?
How will Orgenesis (ORGS) use the $5 million investment?
What is the accelerated purchase option for ORGS shares under this agreement?
